Clinical Research Papers:

Effect of trimetazidine on preventing contrast-induced nephropathy in diabetic patients with renal insufficiency

Ziliang Ye, Haili Lu, Qiang Su _, Xinhua Xian and Lang Li

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:102521-102530. https://doi.org/10.18632/oncotarget.19519

Metrics: PDF 1796 views  |   HTML 2508 views  |   ?  


Ziliang Ye1,2, Haili Lu2, Qiang Su1, Xinhua Xian2 and Lang Li1

1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institue, Nanning, Guangxi, China

2Guangxi Medical University, Nanning, Guangxi, China

Correspondence to:

Qiang Su, email: [email protected]

Lang Li, email: [email protected]

Keywords: trimetazidine, contrast-induced nephropathy, diabetic patients, renal insufficiency

Received: April 25, 2017     Accepted: June 30, 2017     Published: July 24, 2017


Background: Our study sought to assess the effect of trimetazidine (TMZ) on preventing contrast-induced nephropathy (CIN) in diabetic patients with renal insufficiency.

Materials and Methods: 106 diabetic patients with renal insufficiency who were undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI) were enrolled in this study. Standard hydration was administered to both groups (the TMZ group and the control group). In the TMZ group, patients were orally administered TMZ for 48 hours before and 24 hours after CAG and/or PCI. Serum creatinine (Scr), cystatin C and the glomerular filtration rate (eGFR) were measured before as well as 24 hours, 48 hours and 72 hours after contrast media injection. The incidence of CIN and major cardiovascular events (MACE) was also evaluated in both groups.

Results: Scr, cystatin C and the eGRF in the TMZ group were better than those in the control group after 24 hours (OR: 0.78, 95% CI: 0.54–0.82; OR: 0.66, 95% CI: 0.62–0.73; OR: 1.2, 95% CI: 1.02–1.53, respectively), 48 hours (OR: 0.69, 95% CI: 0.52–0.73; OR: 0.76, 95% CI: 0.69–0.84; OR: 1.5, 95% CI: 1.25–1.68, respectively) and 72 hours (OR: 0.82, 95% CI: 0.77–0.91; OR: 0.85, 95% CI: 0.71–0.92; OR: 1.67, 95% CI: 1.33–1.72, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) in the TMZ group was significantly lower than that in the control group (P < 0.05).

Conclusions: Our study suggests that TMZ could reduce the incidence of CIN and MACE in diabetic patients with renal insufficiency who are undergoing CAG and/or PCI.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19519